The National Cancer Institute (NCI) has awarded $7.8 million to physicians at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine to play a leading role in designing, conducting, and enrolling patients in clinical trials through the NCI’s National Clinical Trials Network (NCTN). This award recognizes Siteman’s ability to enroll large numbers of patients in NCI network trials and its scientific leadership in designing and executing cancer clinical trials.
National Clinical Trials Network (NCTN)
Currently about 20,000 patients are enrolled in NCTN trials, including hundreds at Siteman. NCTN is made up of four collaborative groups that conduct cancer clinical trials in adults, one group that conducts cancer clinical trials in children and a Canadian group. The network integrates and streamlines the development of cancer clinical trials, reports Washington University School of Medicine.
Lead Academic Participating Site
With this funding, Siteman now takes on the prestigious responsibility of becoming one of 32 U.S. institutions—most of them NCI-designated cancer centers—to be named a Lead Academic Participating Site in the NCI trials network and the only such site in the states of Missouri, Kansas and Southern Illinois. In fact, Siteman was the first selected as an inaugural lead academic site back in 2014.
Lead Participating Clinical Investigators
Nancy Bartlett, MD (blood cancers)
Benjamin D. Kozower, MD (thoracic oncologist)
David G. Mutch, MD (gynecologic oncologist)
Clifford G. Robinson (radiation oncologist)Source: Washington University School of Medicine